I don't expect the med-tech sector to match the performance of 2013 this year, but I continue to believe that Novadaq (NVDQ)
will be a market-beater. Novadaq has only just begun to show what its
imaging technology can do in terms of clinical results, market share,
and revenue. As time goes on, I expect this company to be one of the
most impressive growth stories in med-tech, and a stock well worth
owning.
Read the full article here:
Novadaq's Story Continues To Come Along
No comments:
Post a Comment